Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dr Chandrashekara S Medical Director

Similar presentations


Presentation on theme: "Dr Chandrashekara S Medical Director"— Presentation transcript:

1 Current status of antibodies (Myositis Profile) in Inflammatory myositis.
Dr Chandrashekara S Medical Director ChanRe Rheumatology & Immunology Center and Research

2 Introduction Idiopathic inflammatory myopathies (IIM) are a group of systemic diseases characterized by an immune mediated attack on skeletal muscle Characterized by Proximal muscle weakness Nonsuppurative inflammation of skeletal muscle Accompanied by extramuscular manifestations Arthritis, Skin lesions, ILD, Calcinosis, Nodules and vasculitis

3 Classification of Idiopathic Inflammatory Myopathy
Dermatomyositis Juvenile Adult Polymyositis T cell mediated Eosinophilic Granulomatous Inclusion body myositis Overlap Syndrome Antisynthetase syndrome Cancer associated myositis

4 What is the role of these AA Epiphenomena or pathognomonic
?

5 Where do we stand

6

7

8

9

10

11

12

13

14

15 Prognosis- yes

16

17 How do we use it Ms X Muscle weakness from 3 month Joint pains
Elevated SGPT/ OT normal GGT Elevated CPK ANA –ve Biopsy patient refusing

18 Case Ctd… Myositis profile Shows positive Jo 1 +++

19 Case Ctd… Evaluation for ILD Management plans
Regular follow up for ILD

20 Myositis profile Mi -2 Myositis specific antibodies are useful in diagnosis and therapeutic management of poly/dermatomyositis. Anti Mi-2 is highly specific for dermatomyositis, found in 15-30% PM-Scl in 50-70% of overlap syndromes with SSc Jo-1 : prevalance is 25-55%. Associated with interstitial lung fibrosis. PL-7 & Pl-3 : prevalance is 3-6% and 3% respectively. Ku Jo-1 PL-12 PL-7 Ro-52 PM-Scl control

21 Thank you….


Download ppt "Dr Chandrashekara S Medical Director"

Similar presentations


Ads by Google